84 related articles for article (PubMed ID: 22067729)
1. HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer.
Hirakawa T; Nakata B; Amano R; Kimura K; Shimizu S; Ohira G; Yamada N; Ohira M; Hirakawa K
Oncology; 2011; 81(3-4):192-8. PubMed ID: 22067729
[TBL] [Abstract][Full Text] [Related]
2. HER2 overexpression correlates with survival after curative resection of pancreatic cancer.
Komoto M; Nakata B; Amano R; Yamada N; Yashiro M; Ohira M; Wakasa K; Hirakawa K
Cancer Sci; 2009 Jul; 100(7):1243-7. PubMed ID: 19432892
[TBL] [Abstract][Full Text] [Related]
3. Chemokine receptor CCR7 expression correlates with lymph node metastasis in pancreatic cancer.
Nakata B; Fukunaga S; Noda E; Amano R; Yamada N; Hirakawa K
Oncology; 2008; 74(1-2):69-75. PubMed ID: 18544997
[TBL] [Abstract][Full Text] [Related]
4. High expression of HER3 is associated with a decreased survival in gastric cancer.
Hayashi M; Inokuchi M; Takagi Y; Yamada H; Kojima K; Kumagai J; Kawano T; Sugihara K
Clin Cancer Res; 2008 Dec; 14(23):7843-9. PubMed ID: 19047113
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Hata S; Sakamoto Y; Yamamoto Y; Nara S; Esaki M; Shimada K; Kosuge T
Ann Surg Oncol; 2012 Feb; 19(2):636-41. PubMed ID: 21863360
[TBL] [Abstract][Full Text] [Related]
6. ErbB-3 predicts survival in ovarian cancer.
Tanner B; Hasenclever D; Stern K; Schormann W; Bezler M; Hermes M; Brulport M; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Steiner E; Sehouli J; Edelmann J; Läuter J; Lessig R; Krishnamurthi K; Ullrich A; Hengstler JG
J Clin Oncol; 2006 Sep; 24(26):4317-23. PubMed ID: 16896008
[TBL] [Abstract][Full Text] [Related]
7. Cyclin E expression and outcome in pancreatic ductal adenocarcinoma.
Skalicky DA; Kench JG; Segara D; Coleman MJ; Sutherland RL; Henshall SM; Musgrove EA; Biankin AV
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1941-7. PubMed ID: 17035403
[TBL] [Abstract][Full Text] [Related]
8. HER-family gene amplification and expression in resected pancreatic cancer.
te Velde EA; Franke AC; van Hillegersberg R; Elshof SM; de Weger RW; Borel Rinkes IH; van Diest PJ
Eur J Surg Oncol; 2009 Oct; 35(10):1098-104. PubMed ID: 19304440
[TBL] [Abstract][Full Text] [Related]
9. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
[TBL] [Abstract][Full Text] [Related]
10. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer.
Javle MM; Gibbs JF; Iwata KK; Pak Y; Rutledge P; Yu J; Black JD; Tan D; Khoury T
Ann Surg Oncol; 2007 Dec; 14(12):3527-33. PubMed ID: 17879119
[TBL] [Abstract][Full Text] [Related]
11. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer.
Waraya M; Yamashita K; Katagiri H; Ishii K; Takahashi Y; Furuta K; Watanabe M
Ann Surg Oncol; 2009 May; 16(5):1231-40. PubMed ID: 19263172
[TBL] [Abstract][Full Text] [Related]
12. [Factors influencing survival of patients with cancer of the pancreatic head after resection].
Gao CT; Li HK; Li Q
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):554-7. PubMed ID: 19950708
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of factors influencing recurrence and metastasis following curative resection of pancreatic ductal adenocarcinoma].
Xie YB; Zhao P; Wang CF; Shan Y; Zhao DB; Liu Q; Bai XF
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):686-9. PubMed ID: 19173911
[TBL] [Abstract][Full Text] [Related]
14. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
[TBL] [Abstract][Full Text] [Related]
15. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
16. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage.
Thybusch-Bernhardt A; Beckmann S; Juhl H
Int J Surg Investig; 2001; 2(5):393-400. PubMed ID: 12678544
[TBL] [Abstract][Full Text] [Related]
18. The ratio of metastatic/resected lymph nodes is an independent prognostic factor in patients with node-positive pancreatic head cancer.
Sierzega M; Popiela T; Kulig J; Nowak K
Pancreas; 2006 Oct; 33(3):240-5. PubMed ID: 17003644
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.
Scorilas A; Karameris A; Arnogiannaki N; Ardavanis A; Bassilopoulos P; Trangas T; Talieri M
Br J Cancer; 2001 Jun; 84(11):1488-96. PubMed ID: 11384099
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
